Literature DB >> 16872037

AA amyloidosis in psoriatic arthritis.

J G Ryan1, A M Dorman, P G O'Connell.   

Abstract

BACKGROUND: Amyloidosis is an extremely rare complication of psoriatic arthritis (PsA) and is associated with a poor prognosis. We report a case of amyloidosis secondary to severe PsA in a young patient and the course of his disease over a 13-year period of aggressive immunosuppression.
METHODS: Diagnosis of renal amyloidosis was made on biopsy: multi-agent immunosuppressive therapy was continued with stabilisation of renal function.
RESULTS: Marked deterioration in renal function subsequently occurred following a reduction in cyclosporin A (CyA) dose and repeat biopsy confirmed worsening amyloidosis.
CONCLUSION: This case report emphasises the need for aggressive control of the inflammatory response in secondary amyloidosis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16872037     DOI: 10.1007/bf03167957

Source DB:  PubMed          Journal:  Ir J Med Sci        ISSN: 0021-1265            Impact factor:   1.568


  7 in total

Review 1.  Molecular mechanisms of amyloidosis.

Authors:  Giampaolo Merlini; Vittorio Bellotti
Journal:  N Engl J Med       Date:  2003-08-07       Impact factor: 91.245

2.  Secondary amyloidosis complicating arthropathic psoriasis.

Authors:  S Tsuda; Y Maeyama; N Yamamoto; Y Sasai; K Yoshida
Journal:  Clin Exp Dermatol       Date:  1996-03       Impact factor: 3.470

Review 3.  The systemic amyloidoses.

Authors:  R H Falk; R L Comenzo; M Skinner
Journal:  N Engl J Med       Date:  1997-09-25       Impact factor: 91.245

Review 4.  Psoriatic spondyloarthropathy with secondary amyloidosis.

Authors:  Q Ahmed; M Chung-Park; K Mustafa; M A Khan
Journal:  J Rheumatol       Date:  1996-06       Impact factor: 4.666

5.  Amyloidosis in a nationwide series of 1666 subjects with rheumatoid arthritis who died during 1989 in Finland.

Authors:  R Myllykangas-Luosujärvi; K Aho; H Kautiainen; M Hakala
Journal:  Rheumatology (Oxford)       Date:  1999-06       Impact factor: 7.580

6.  Cytostatic therapy for AA amyloidosis complicating psoriatic spondyloarthropathy.

Authors:  S Mpofu; L S Teh; P J Smith; R J Moots; P N Hawkins
Journal:  Rheumatology (Oxford)       Date:  2003-02       Impact factor: 7.580

7.  Anti-tumor necrosis factor alpha therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides: a followup report of tolerability and efficacy.

Authors:  Jacques-Eric Gottenberg; Florence Merle-Vincent; Fabrice Bentaberry; Yannick Allanore; Francis Berenbaum; Bruno Fautrel; Bernard Combe; Antoine Durbach; Jean Sibilia; Maxime Dougados; Xavier Mariette
Journal:  Arthritis Rheum       Date:  2003-07
  7 in total
  2 in total

Review 1.  Course and Prognosis of AA Amyloidosis in Patients with Psoriatic Arthritis: Report of Three Cases from a Single Center Cohort and Review of the Literature.

Authors:  Murat Bektaş; Nevzat Koca; Burak Ince; Yasemin Yalçınkaya; Bahar Artım Esen; M Lale Öcal; Ahmet Gül; Murat Inanç
Journal:  Mediterr J Rheumatol       Date:  2022-06-30

2.  What is your diagnosis?

Authors:  L Aghaghazvini; P Karami; O Yeganeh; Sh Aghaghazvini
Journal:  Iran J Radiol       Date:  2011-09-25       Impact factor: 0.212

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.